首页> 美国卫生研究院文献>Genes >PheWAS-Based Systems Genetics Methods for Anti-Breast Cancer Drug Discovery
【2h】

PheWAS-Based Systems Genetics Methods for Anti-Breast Cancer Drug Discovery

机译:基于PheWAS的系统遗传学方法用于抗乳腺癌药物的发现

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Breast cancer is a high-risk disease worldwide. For such complex diseases that are induced by multiple pathogenic genes, determining how to establish an effective drug discovery strategy is a challenge. In recent years, a large amount of genetic data has accumulated, particularly in the genome-wide identification of disorder genes. However, understanding how to use these data efficiently for pathogenesis elucidation and drug discovery is still a problem because the gene–disease links that are identified by high-throughput techniques such as phenome-wide association studies (PheWASs) are usually too weak to have biological significance. Systems genetics is a thriving area of study that aims to understand genetic interactions on a genome-wide scale. In this study, we aimed to establish two effective strategies for identifying breast cancer genes based on the systems genetics algorithm. As a result, we found that the GeneRank-based strategy, which combines the prognostic phenotype-based gene-dependent network with the phenotypic-related PheWAS data, can promote the identification of breast cancer genes and the discovery of anti-breast cancer drugs.
机译:乳腺癌是全世界的高危疾病。对于由多种致病基因诱导的复杂疾病,确定如何建立有效的药物发现策略是一个挑战。近年来,已积累了大量的遗传数据,尤其是在全基因组范围的疾病基因鉴定中。但是,了解如何有效地利用这些数据进行发病机理阐明和药物发现仍然是一个问题,因为通过高通量技术(如全基因组关联研究(PheWAS))识别的基因-疾病关联通常太弱而无法进行生物学研究。意义。系统遗传学是一个蓬勃发展的研究领域,旨在了解全基因组范围内的遗传相互作用。在这项研究中,我们旨在建立基于系统遗传算法的两种有效的乳腺癌基因识别策略。结果,我们发现基于GeneRank的策略结合了基于预后表型的基因依赖性网络与与表型相关的PheWAS数据,可以促进乳腺癌基因的鉴定和抗乳腺癌药物的发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号